Literature DB >> 23529713

Annual all-cause healthcare costs among influenza patients with and without influenza-related complications: analysis of a United States managed care database.

Sudeep Karve1, Derek Misurski, Guillermo Herrera-Taracena, Keith L Davis.   

Abstract

BACKGROUND: Several studies have reported that patients with influenza have a high risk of developing complications such as secondary infections, exacerbation of cardiovascular conditions and asthma. However, limited data exists on the healthcare cost burden for influenza patients with and without influenza-related complications.
OBJECTIVE: We compared healthcare utilization and costs among influenza patients with related complications versus patients without complications.
METHODS: In this retrospective database analysis (LifeLink database: 1998-2009) of a US managed care database, we selected patients diagnosed with influenza during influenza seasons and categorized them as complicated or uncomplicated based on the presence or absence of a diagnosis for a related complication in the year following their influenza diagnosis. Multivariable regression analyses were conducted to compare all-cause utilization and costs (adjusted to 2009 US dollars) between the two groups.
RESULTS: We identified 54,469 patients of which ~65 % had evidence for at least one complication. Patients with complicated influenza had a 1.5-fold higher rate of inpatient utilization compared with uncomplicated cases (p < 0.001). Significantly higher covariate-adjusted predicted mean annual costs were also observed among complicated influenza patients across all care (p-values <0.001 for all comparisons).
CONCLUSION: Healthcare costs were twice as high among influenza patients with complications versus those without, with inpatient and outpatient services being the primary cost drivers. Now with the universal recommendation for seasonal influenza vaccination for all individuals ≥6 months of age, improvement in coverage rates may help reduce the healthcare utilization and costs associated with influenza and associated complications.

Entities:  

Mesh:

Year:  2013        PMID: 23529713     DOI: 10.1007/s40258-013-0020-6

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  6 in total

1.  Surges of advanced medical support associated with influenza outbreaks.

Authors:  J C King; J E Schweinle; R J Hatchett; Y Gao; R Lichenstein; J Zhou
Journal:  Epidemiol Infect       Date:  2017-06-09       Impact factor: 4.434

2.  Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany--results of a database analysis from May 2010 to April 2012.

Authors:  Birgit Ehlken; Anastassia Anastassopoulou; Johannes Hain; Claudia Schröder; Klaus Wahle
Journal:  BMC Public Health       Date:  2015-06-21       Impact factor: 3.295

3.  Health care costs of influenza-related episodes in high income countries: A systematic review.

Authors:  Carlo Federici; Marianna Cavazza; Francesco Costa; Claudio Jommi
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

4.  Epidemiology and direct healthcare costs of Influenza-associated hospitalizations - nationwide inpatient data (Germany 2010-2019).

Authors:  David Goettler; Patricia Niekler; Johannes G Liese; Andrea Streng
Journal:  BMC Public Health       Date:  2022-01-15       Impact factor: 3.295

Review 5.  The economic burden of influenza among adults aged 18 to 64: A systematic literature review.

Authors:  Caroline de Courville; Sarah M Cadarette; Erika Wissinger; Fabián P Alvarez
Journal:  Influenza Other Respir Viruses       Date:  2022-02-05       Impact factor: 4.380

6.  Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.

Authors:  Laure-Anne Van Bellinghen; Alen Marijam; Gabriela Tannus Branco de Araujo; Jorge Gomez; Ilse Van Vlaenderen
Journal:  Braz J Infect Dis       Date:  2018-01-18       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.